Skip to content

Study · Non-randomized trial · n = 10 · 1988

4 results

Glucagon and glucose tolerance in liver cirrhosis.

Greco AV, Altomonte L, Ghirlanda G, D'Anna LM, Manna R, Caputo S, Uccioli L

Acta endocrinologica1 Jul 1988Cited by 2 (Europe PMC)

PMID2899368 (opens in a new tab)DOI10.1530/acta.0.1180337 (opens in a new tab)PepBankPUB-02899368
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In normal subjects, glucagon infusion did not impair glucose tolerance versus saline.

    In plain wordsIn normal subjects, glucagon did not worsen glucose tolerance compared with saline.

    Peptide
    Glucagon
    Outcome
    No significant changeGlucose tolerance in normal subjects
    Study

    n = 10

    Comparator
    Saline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 ng.kg-1.min-1 · infusionAs given in this study (human).

    Source sentences

    Summary
    Glucagon infusion did not impair glucose tolerance, neither in normal subjects nor in patients with cirrhosis.
    1 context sentence
    Summary · context
    The plasma glucose response to an oral glucose load (75 g) was determined in 10 control subjects and in 10 cirrhotic patients, after infusions of: glucagon (3 ng.kg-1.min-1) or saline (154 mmol/l); somatostatin (SRIH) (500 micrograms/h); and SRIH plus glucagon (3 ng.kg-1.min-1).
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with cirrhosis, glucagon infusion did not impair glucose tolerance versus saline.

    In plain wordsIn patients with cirrhosis, glucagon did not worsen glucose tolerance compared with saline.

    Peptide
    Glucagon
    Outcome
    No significant changeGlucose tolerance in cirrhosis
    Study

    n = 10

    Comparator
    Saline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 ng.kg-1.min-1 · infusionAs given in this study (human).

    Source sentences

    Summary
    Glucagon infusion did not impair glucose tolerance, neither in normal subjects nor in patients with cirrhosis.
    1 context sentence
    Summary · context
    The plasma glucose response to an oral glucose load (75 g) was determined in 10 control subjects and in 10 cirrhotic patients, after infusions of: glucagon (3 ng.kg-1.min-1) or saline (154 mmol/l); somatostatin (SRIH) (500 micrograms/h); and SRIH plus glucagon (3 ng.kg-1.min-1).
  3. 03HumanNon-randomized trialEfficacy outcome

    In normal subjects, adding glucagon to somatostatin further impaired glucose tolerance compared with somatostatin alone.

    In plain wordsIn normal subjects, glucagon with somatostatin worsened glucose tolerance compared with somatostatin alone.

    Peptide
    Glucagon
    Outcome
    DecreaseGlucose tolerance during somatostatin in normal subjects
    Study

    n = 10

    Comparator
    Somatostatin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 ng.kg-1.min-1 · infusionAs given in this study (human).

    Source sentences

    Summary
    Both in normal subjects and in cirrhotic patients, SRIH plus glucagon infusion further impaired glucose tolerance, presumably as a result of excess glucagon and concomitant insulin deficiency.
    2 context sentences
    Summary · context
    On the other hand, in both groups glucose tolerance was impaired by SRIH infusion, presumably owing to an absolute insulin deficiency.
    Summary · context
    The plasma glucose response to an oral glucose load (75 g) was determined in 10 control subjects and in 10 cirrhotic patients, after infusions of: glucagon (3 ng.kg-1.min-1) or saline (154 mmol/l); somatostatin (SRIH) (500 micrograms/h); and SRIH plus glucagon (3 ng.kg-1.min-1).
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with cirrhosis, adding glucagon to somatostatin further impaired glucose tolerance compared with somatostatin alone.

    In plain wordsIn patients with cirrhosis, glucagon with somatostatin worsened glucose tolerance compared with somatostatin alone.

    Peptide
    Glucagon
    Outcome
    DecreaseGlucose tolerance during somatostatin in cirrhosis
    Study

    n = 10

    Comparator
    Somatostatin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 ng.kg-1.min-1 · infusionAs given in this study (human).

    Source sentences

    Summary
    Both in normal subjects and in cirrhotic patients, SRIH plus glucagon infusion further impaired glucose tolerance, presumably as a result of excess glucagon and concomitant insulin deficiency.
    2 context sentences
    Summary · context
    On the other hand, in both groups glucose tolerance was impaired by SRIH infusion, presumably owing to an absolute insulin deficiency.
    Summary · context
    The plasma glucose response to an oral glucose load (75 g) was determined in 10 control subjects and in 10 cirrhotic patients, after infusions of: glucagon (3 ng.kg-1.min-1) or saline (154 mmol/l); somatostatin (SRIH) (500 micrograms/h); and SRIH plus glucagon (3 ng.kg-1.min-1).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.